1-4 of 4
Kednapa Thavorn
Close
Sort by
Journal Articles

Clinical Benefits, Harms, and Cost-Effectiveness of Indefinite Anticoagulant Therapy for First Unprovoked Venous Thromboembolism: A Decision Analytic Modelling Study

Faizan Khan, Doug Coyle, Kednapa Thavorn, Sasha van Katwyk, Tobias Tritschler, Brian Hutton, Gregoire Le Gal, Marc A. Rodger, Dean Fergusson
Journal: Blood
Blood (2022) 140 (Supplement 1): 7858–7859.
https://doi.org/10.1182/blood-2022-158006
Published: 2022
Journal Articles

Decision Analysis of Allogeneic Stem Cell Transplantation for Primary Myelofibrosis

Christopher Cipkar, Srishti Kumar, Kednapa Thavorn, Natasha Kekre
Journal: Blood
Blood (2021) 138 (Supplement 1): 2923.
https://doi.org/10.1182/blood-2021-147376
Published: 2021
Journal Articles

Cost-Utility Analysis of Apixaban Compared to Usual Care for the Primary Thromboprophylaxis of Ambulatory Cancer Patients Initiating Chemotherapy

Miriam Kimpton, MD, Srishti Kumar, MSc, Philip S. Wells, MDMSc,FRCP, Marc Carrier, MD, Kednapa Thavorn, MPharm, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 329.
https://doi.org/10.1182/blood-2019-127286
Published: 2019
Journal Articles

A Decision Model to Estimate Risk Thresholds for Guiding Duration of Anticaogulation in Unprovoked Venous Thromboembolism

Faizan Khan, BSc, Kednapa Thavorn, MPharm, PhD, Doug Coyle, MA, MSc, PhD, Marc A Rodger, MD MSc, FRCPC
Journal: Blood
Blood (2017) 130 (Supplement 1): 4641.
https://doi.org/10.1182/blood.V130.Suppl_1.4641.4641
Published: 2017